S
Stilla Technologies
Biotechnology company that focuses on accelerating the development of next-generation genetic tests
About Stilla Technologies
Stilla Technologies is a biotechnology startup that specializes in digital PCR (Polymerase Chain Reaction) workflows. The company's flagship product, Nio™+, is a powerful tool that simplifies the process of DNA quantification, a critical procedure in genetic research and diagnostics. The Nio™+ system supports 7 colors, has a capacity of 768 samples per 8-hour workday, and features continuous loading and user-friendly software.
Stilla Technologies serves a diverse range of clients, including research institutions, healthcare providers, and biotech companies. The company operates in the global biotechnology market, with a particular focus on genetic research and diagnostics.
The business model of Stilla Technologies revolves around the sale of its Nio™+ system and related products, such as its Crystal Digital PCR® Kits. These kits are used to detect and quantify specific genetic mutations in a single test, providing precise and reliable results.
Stilla Technologies has also developed applications for detecting ESR1 mutations in breast cancer samples and EGFR mutations in lung cancer samples. Additionally, the company offers a solution for on- and off-target detection in CRISPR-edited mammalian cell lines, a process that is typically laborious and time-consuming.
In summary, Stilla Technologies is a biotech startup that provides powerful and user-friendly solutions for DNA quantification, mutation detection, and genetic modification screening.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2013
- Headquarters
- Villejuif, France
- Employees
- 84
- Open positions
- 1
- Dealroom signal
- 63.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, DNA, Genetics and genomics, Spinout, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, radar de l'innovation, observatoire industrial tech, medical testing
- Business model
- SaaS
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Feb 2025 | $225M | $225M | Bio-Rad Laboratories | ↗ |
| SERIES COther financing | Feb 2024 | $27M | $106M | Illumina Ventures · BNP Paribas Développement · Kurma Partners · ADIN | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Stilla Technologies is 1K monthly website visits, down 76.7% over the last three months. Stilla Technologies's team declined 15.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Series B and later5 investors entered at this stage
Casdin Capital
European Investment Bank
ADIN
Paris Saclay Seed Fund
Zhongyuan Yuzi Investment Group
Other known investors3 additional known investors
Bio-Rad Laboratories
École Polytechnique - IP Paris
IP Paris
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Stilla Technologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Stilla Technologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.